cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-01. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Various reform strategies were proposed for healthcare, and in March 2010, the Patient Protection and Affordable Care Act was enacted as a means of health care reform. CBO reduced its per capita Medicare spending assumptions by $1,000 for 2014 and $2,300 for 2019, relative to its 2010 estimate for those years. If this trend continues, it will significantly improve the long-term budget outlook. Social Security is a social insurance program officially called "Old-Age, Survivors, and Disability Insurance" (OASDI), in reference to its three components. It is primarily funded through a dedicated payroll tax of 12.4%. During 2016, total benefits of $910 billion were paid out, versus $882 billion in 2015, an increase of $28 billion or 3%. Social Security's total expenditures have exceeded its non-interest income since 2010. The deficit of non-interest income relative to cost was about $49 billion in 2010, $45 billion in 2011, and $55 billion in 2012. During 2010, an estimated 157 million people paid into the program and 54 million received benefits, roughly 2.91 workers per beneficiary. Since the Greenspan Commission in the early 1980s, Social Security has cumulatively collected far more in payroll taxes dedicated to the program than it has paid out to recipients—nearly $2.6 trillion in 2010. This annual surplus is credited to Social Security trust funds that hold special non-marketable Treasury securities. This surplus amount is commonly referred to as the "Social Security Trust Fund." The proceeds are paid into the U.S.
=== Disadvantages === Reduced immunogenicity compared to attenuated vaccines Require adjuvants to improve immunogenicity Often require multiple doses ("booster" doses) to provide long-term immunity Can be difficult to isolate the specific antigen(s) which will invoke the necessary immune response It is not easy to supervise conjugation chemistry which leads to noncontinuous variation
Historically, the typical HPLC column consists of high-purity particulate silica compressed into stainless steel tubing. To decrease run times and increase selectivity, smaller diffusion distances have been pursued. To achieve smaller diffusion distances there has been a decrease in the particle sizes. However, as the particle size decreases, the backpressure (for a given column diameter and a given volumetric flow) increases proportionally. Pressure is inversely proportional to the square of the particle size; i.e., when particle size is halved, pressure increases by a factor of four. This is because as the particle sizes get smaller, the interstitial voids (the spaces between the particles) do as well, and it is harder to push the compounds through the smaller spaces. Modern HPLC systems are generally designed to withstand about 18,000 pounds per square inch (1,200 bar) of backpressure in order to deal with this problem. Monoliths also have very short diffusion distances, while also providing multiple pathways for solute dispersion. Packed particle columns have pore connectivity values of about 1.5, while monoliths have values ranging from 6 to greater than 10. This means that, in a particulate column, a given analyte may diffuse into and out of the same pore, or enter through one pore and exit through a connected pore. By contrast, an analyte in a monolith is able to enter one channel and exit through any of 6 or more different venues. Little of the surface area in a monolith is inaccessible to compounds in the mobile phase.
Sources: en.wikipedia.org
=== Glucocorticoid activity === CPA is an agonist of the glucocorticoid receptor (GR), and has weak and partial glucocorticoid activity at high doses. In animals, CPA suppresses the secretion of adrenocorticotropic hormone (ACTH) from the pituitary gland, suppresses the production of corticosteroids like cortisol and corticosterone by the adrenal cortices, and decreases the weights of the adrenal glands and thymus. Conversely however, CPA shows no anti-inflammatory or eosinophilic effects in animals. As such, CPA, as well as related antiandrogens, show only some of the typical effects of glucocorticoids. CPA may produce mild glucucorticoid actions at high doses of more than 100 mg/day in humans. Clinically, the glucocorticoid effects of CPA appear to be relevant only at high doses in people with small body sizes (CPA exposure of more than 80 to 100 mg/m2), namely in the treatment of children with precocious puberty. No signs of secondary adrenal insufficiency have been observed with CPA. While various studies have clearly shown reduced cortisol and ACTH levels and ACTH responsiveness in humans with CPA therapy, some studies contradict these findings and report no such effects even with high doses of CPA. Due to negative feedback on the hypothalamic–pituitary-adrenal (HPA) axis, administration of exogenous glucocorticoids such as prednisone and dexamethasone suppress the secretion of adrenocorticotropic hormone (ACTH) from the pituitary gland and the production of cortisol from the adrenal glands.
== External links == Niedzielin K, Kordecki H, Birkenfeld B (October 2001). "A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome". European Journal of Gastroenterology & Hepatology. 13 (10): 1143–1147. doi:10.1097/00042737-200110000-00004. PMID 11711768. S2CID 45444717. www.DocGuide.com another reference about IBS Type strain of Lactobacillus plantarum at BacDive - the Bacterial Diversity Metadatabase
After one round of selection of an alpha-L-threofuranosyl nucleic acid (TNA) polymerase, they demonstrated roughly 14-fold improvement in activity and >99% correct placement of residues in a growing polypeptide. In 2017, S. S. Terekhov et al. developed monodisperse microfluidic double water-in-oil-in-water emulsion (MDE) sorting, which they combined with FACS followed by liquid chromatography-mass spectrometry (LC-MS) and next-generation sequencing (NGS). The authors demonstrated high sensitivity sorting of enzymatically active yeast cells from non-active cells using fluorescence. Further, they showed the ability of their MDE-FACS system to interrogate interactions between target and effector cells within droplets without interference from other yeast and bacterial cells. Rather than developing new platforms, some groups have focused on the optimization of existing methods, tools and platforms to simplify and improve their ease of use by non-experts. In 2017, Sukovitch et al.created a system to produce monodisperse or approximately equal size DEs by cutting out the coating process required for DE chips. Various groups have altered surfactant types and concentrations to simplify reagent delivery in SEs and DEs. In 2018, Ma et al. presented a dual-channel microfluidic droplet screening system (DMDS). The system uses fluorogenic tags to sort SEs by two different properties of a target enzyme at the same time. Using DMDS, Ma and coworkers directed the evolution of a highly enantioselective esterase using multiple enzymatic properties. In 2020, Brower et al.
=== Principle and measurement methods === In the U.S., standard methods have been established by the National Institute for Occupational Safety and Health (NIOSH) and another by U.S. OSHA. Each method uses a single component solvent; butanol and hexane cannot be sampled, however, on the same sample matrix using the NIOSH or OSHA method. VOCs are quantified and identified by two broad techniques. The major technique is gas chromatography (GC). GC instruments allow the separation of gaseous components. When coupled to a flame ionization detector (FID) GCs can detect hydrocarbons at the parts per trillion levels. Using electron capture detectors, GCs are also effective for organohalide such as chlorocarbons. The second major technique associated with VOC analysis is mass spectrometry, which is usually coupled with GC, giving the hyphenated technique of GC-MS. Direct injection mass spectrometry techniques are frequently utilized for the rapid detection and accurate quantification of VOCs. PTR-MS is among the methods that have been used most extensively for the on-line analysis of biogenic and anthropogenic VOCs. PTR-MS instruments based on time-of-flight mass spectrometry have been reported to reach detection limits of 20 pptv after 100 ms and 750 ppqv after 1 min. measurement (signal integration) time. The mass resolution of these devices is between 7000 and 10,500 m/Δm, thus it is possible to separate most common isobaric VOCs and quantify them independently.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.